Trials / Terminated
TerminatedNCT03774784
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.
Detailed description
Refer to www.studyALECT2.com
Conditions
Timeline
- Start date
- 2019-01-29
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
- First posted
- 2018-12-13
- Last updated
- 2020-06-16
Locations
31 sites across 6 countries: United States, Egypt, India, Malaysia, Mexico, United Kingdom
Source: ClinicalTrials.gov record NCT03774784. Inclusion in this directory is not an endorsement.